NCCN Guidelines

Guidelines

• NCCN Guidelines Version 2.2024

Evidence Blocks

• NCCN Guidelines with Evidence Blocks Version 2.2024

Frameworks

• Basic Resources (English) Version 4.2022

• Core Resources (English) Version 4.2022

• Enhanced Resources (English) Version 4.2022

Guidelines for Patients

• Invasive Breast Cancer-English Version 2024

• Metastatic Breast Cancer-English Version 2024

• Ductal Carcinoma In Situ-English Version 2024

• Inflammatory Breast Cancer-English Version 2023

• Ductal Carcinoma In Situ-Spanish - Latin America Version 2023

• Metastatic Breast Cancer-Spanish - Latin America Version 2023

• Invasive Breast Cancer-Spanish - Latin America Version 2023

• Inflammatory Breast Cancer-Spanish - Latin America Version 2023

Educational Events and Programs

Calendar of Events

Continuing Education

• NCCN Guidelines® Insights - Breast Cancer, Version 4.2023

• NCCN Guidelines® Insights - Breast Cancer Screening and Diagnosis, Version 1.2023

• Recorded Presentation from the NCCN Pharmacy Updates: The Role of PD-L1 Therapy in the Early Treatment of Triple Negative Breast Cancer

• Clinical Scenario #2: Applying Biomarkers in Breast Cancer

• Monthly Oncology Tumor Boards: Sequencing Therapies for Patients with Metastatic HER2-Negative Breast Cancer

• Archived Monthly Oncology Tumor Boards: Sequencing Therapies for Patients with Metastatic HER2-Negative Breast Cancer

• Multigene and Biomarker Testing in Breast Cancer

• Neoadjuvant/Adjuvant Treatment for Breast Cancer with SABCS Updates

• Locoregional Management of Breast Cancer with SABCS Updates

• Advances in the Management of Metastatic Breast Cancer with SABCS Updates

• Issues with Sexuality and Sexual Function in Patients with Breast Cancer

• Cardiovascular Health After Breast Cancer Treatment

International

Disclosures

• Disclosure Policy

• Panel Member Disclosures

• Panel Member Disclosures by Meeting Date

• End User License Agreement